Basic information Safety Supplier Related

7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-

Basic information Safety Supplier Related

7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]- Basic information

Product Name:
7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-
Synonyms:
  • N-Methyl-N-[(3R,4R)-4-methyl-1-(phenylmethyl)-3-piperidinyl]-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-
  • Tofacitinib-13
  • Tofacitinib impurity 9/N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • N-Des(-3'-oxopropanenitrile)-N-(methyl)benzene Tofacitinib N-Hydrosulfonylmethylbenzene
  • 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, N-methyl-N-[(3R,4R)-4-me...
  • Azilsartan medoxomil impurity341
  • Tofatinib Impurity 4
CAS:
923036-30-0
MF:
C27H31N5O2S
MW:
489.63
Mol File:
923036-30-0.mol
More
Less

7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]- Chemical Properties

Melting point:
180-183℃
Boiling point:
655.2±65.0 °C(Predicted)
Density 
1.27±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
pka
9.02±0.10(Predicted)
Appearance
White to off-white Solid
More
Less

7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]- Usage And Synthesis

Uses

A useful intermediate for the formal asymmetric synthesis of (+)?-?Tofacitinib. An impurity of Tofacitinib(C781351).

Synthesis

477600-70-7

479633-63-1

923036-30-0

(3R,4R)-1-benzyl-4-methyl-3-methylamino-piperidine (4.3 g, 19.7 mmol, 1.0 eq.) was dissolved in 180 mL of water, followed by the addition of 4-chloro-7-toluenesulfonyl-7H-pyrrolo[2,3-D]pyrimidine (12.3 g, 39.2 mmol, 2.0 eq.) and potassium carbonate (16.6 g, 119 mmol. 6.0 eq.). The reaction mixture was stirred at 100 °C for 16 h and then cooled to room temperature. After completion of the reaction, the reaction was extracted three times with ethyl acetate (500 mL), the organic phases were combined and washed sequentially with water and brine. The organic layer was dried with anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The crude product was purified by column chromatography (eluent: ethyl acetate/petroleum ether=1:1) to afford N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-toluenesulfonyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (8.6 g, 90% yield) as a pale yellow solid.

References

[1] Patent: CN103896946, 2018, B. Location in patent: Paragraph 0084; 0085; 0086
[2] Journal of Medicinal Chemistry, 2008, vol. 51, # 24, p. 8012 - 8018

7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-Supplier

Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Email
chenyj@titansci.com
Jiangsu Vcare PharmaTech Co., Ltd.
Tel
025-58741518 13327700685
Email
sales@vcarepharmatech.com
Synches Co., Ltd.
Tel
021-53292253
Email
biz@synches.com
Alputon Inc.
Tel
021-60753308-14013
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Email
marketing@targetmol.com